Califia Bio
Pharmaceuticals, Sorrento Vly Rd, San Diego, , 92121, California, 11575, United States, 1-10 Employees
Who is CALIFIA BIO
Califia Bio Inc. is collaborating with several NIH-funded academic research groups to develop treatments for unmet therapeutic needs in the areas of neurodegenerative disease, inflammatio...
Read More
-
Headquarters: 11575 Sorrento Vly Rd, San Diego, California, 92121, United States
-
Date Founded: 2008
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
-
CEO:
Val Goodfellow
Email
Phone
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 621999 |
Show More
Does something look wrong? Fix it. | View contact records from CALIFIA BIO
Califia Bio Org Chart and Mapping
Similar Companies to Califia Bio
AnaptysBio
-
51-200
-
$ 25 Million to 50 Million
Arcturus Therapeutics
-
51-200
-
$ 25 Million to 50 Million
Escient Pharmaceuticals
-
11-50
-
$ 10 Million to 25 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Califia Bio
Answer: Califia Bio's headquarters are located at Sorrento Vly Rd, San Diego, , 92121, California, 11575, United States
Answer: Califia Bio's official website is https://califiabio.com
Answer: Califia Bio's revenue is Under $1 Million
Answer: Califia Bio's SIC: 2834
Answer: Califia Bio's NAICS: 621999
Answer: Califia Bio has 1-10 employees
Answer: Califia Bio is in Pharmaceuticals
Answer: Califia Bio top competitors include: AnaptysBio , Arcturus Therapeutics , Escient Pharmaceuticals
Answer: Califia Bio contact info: Phone number: Website: https://califiabio.com
Answer: Califia Bio Inc. is collaborating with several NIH-funded academic research groups to develop treatments for unmet therapeutic needs in the areas of neurodegenerative disease, inflammation and organ failure. Califia Bio is currently developing two series of mixed lineage kinase (MLK3) inhibitors for potential treatment of HIV-Associated Neurocognitive Disorder (HAND), Parkinsons Disease and Heart Failure. We are exploring the development of inhibitors of dual leucine zipper kinase (DLK) as potential treatments for glaucoma and other neuropathic disorders. Califia Bios expertise is in hit generation, lead optimization and preclinical development. We have partnered with world-class academic biology groups to bring important discoveries to the clinic.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month